Northwest Biotherapeutics | NWBO - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Agenus USD -199.08M 22.15M 2026-06
AstraZeneca USD 11.55B 674M 2026-09
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Celldex Therapeutics USD 649.47M 65.1M 2026-09
Eisai JPY 209.6B 6.14B 2026-06
Merck USD 10.75B 5.02B 2026-09
Northwest Biotherapeutics USD 11.39M 120.04M 2026-03
Pfizer USD 89B 3.81B 2026-09
Plus Therapeutics USD 8.15M 1.04M 2026-03
Roche Holding CHF 18.9B 2.12B 2026-06